{
    "root": "77f92606-1bbf-4ece-9364-49d9bf37b9e6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lurasidone Hydrochloride",
    "value": "20250505",
    "ingredients": [
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE"
        },
        {
            "name": "LURASIDONE HYDROCHLORIDE",
            "code": "O0P4I5851I"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "indications": "Lurasidone hydrochloride tablets are indicated for:\n                  • Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies (14.1)] .\n                  • Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies (14.2)]. \n                  \n                  • Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies (14.2)].",
    "contraindications": "Lurasidone hydrochloride tablets should be taken with food (at least 350 calories). Administration with food substantially increases the absorption of Lurasidone hydrochloride tablets ( 2.3 , 12.3 ). Indication Starting Dose Recommended Dose Schizophrenia – adults ( 2.1 ) 40 mg per day 40 mg to 160 mg per day Schizophrenia-adolescents (13 to 17) ( 2.1 ) 40 mg per day 40 mg to 80 mg per day Bipolar Depression – adults ( 2.2 ) 20 mg per day 20 mg to 120 mg per day Bipolar Depression – pediatric patients (10 to 17 years) ( 2.2 ) 20 mg per day 20 mg to 80 mg per day • Moderate and Severe Renal Impairment: Recommended starting dose is 20 mg per day, and the maximum recommended dose is 80 mg per day ( 2.4 , 8.6 ). • Moderate and Severe Hepatic Impairment: Recommended starting dose is 20 mg per day. The maximum recommended dose is 80 mg per day in moderate  hepatic impairment and 40 mg per day in severe hepatic impairment ( 2.5 , 8.7 ). • Concomitant Use of a Moderate CYP3A4 inhibitor (e . g., diltiazem): Lurasidone hydrochloride tablets dose should be reduced to half of the original dose level. Recommended starting dose is 20 mg per day. Maximum recommended dose is 80 mg per day ( 2.6 , 7.1 ). • Concomitant Use of a Moderate CYP3A4 Inducer: It may be necessary to increase the dose of lurasidone hydrochloride tablets ( 2.6 , 7.1 ).",
    "warningsAndPrecautions": "Lurasidone hydrochloride tablets 20 mg are white to off white coloured, round, biconvex shaped, film coated tablets plain on one side and debossed \"64\" on other side.\n                  Bottles of 30                                                                    NDC 13668-464-30\n                  Bottles of 90                                                                    NDC 13668-464-90\n                  \n                     Lurasidone hydrochloride tablets 40 mg are white to off white coloured, round, biconvex shaped, film coated tablets plain on one side and debossed \"65\" on other side.\n                  \n                  Bottles of 30                                                                    NDC 13668-465-30\n                  Bottles of 90                                                                    NDC 13668-465-90\n                  Lurasidone hydrochloride tablets 60 mg are white to off white coloured, oblong shaped, film coated tablets plain on one side and debossed “509” on other side.\n                  Bottles of 30                                                                    NDC 13668-737-30\n                  Bottles of 90                                                                    NDC 13668-737-90\n                  \n                     Lurasidone hydrochloride tablets 80 mg are pale green coloured, oval shaped, film coated tablets plain on one side and debossed \"466\" on other side.\n                  \n                  Bottles of 30                                                                    NDC 13668-466-30\n                  Bottles of 90                                                                    NDC 13668-466-90\n                  \n                     Lurasidone hydrochloride tablets 120 mg are white to off white coloured, oval shaped, film coated tablets plain on one side and debossed \"465\" on other side. \n                  \n                  Bottles of 30                                                                    NDC 13668-467-30\n                  Bottles of 90                                                                    NDC 13668-467-90\n                  \n                     Storage\n                  \n                  Store lurasidone hydrochloride tablets at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP Controlled Room Temperature].",
    "adverseReactions": "• Known hypersensitivity to lurasidone HCl or any components in the formulation.  Angioedema has been observed with lurasidone \n       \n \n  [see Adverse Reactions (\n        \n  \n   6.1)]\n       \n \n  .\n      \n\n \n                  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) \n       \n \n  [see Drug Interactions (\n        \n  \n   7.1)]. \n       \n \n  \n                  \n                  • Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) \n       \n \n  [see Drug Interactions (\n        \n  \n   7.1)]."
}